The PharmaTell Team has been busy curating Quarterly Results reports & upcoming conference planners + keeping up with Biogen next steps.

This week the team has been enjoying the spring holidays and keeping their eyes on some of the recent news from AACR and learning a bit more

This week the team has been keeping their eyes on 1Q22 Patient Volume/Procedure Updates and the Aduhelm CMS Decision.

We are excited to share the latest upgrades to PharmaTell Studio making it even easier for you to keep your eyes on you & your competition.

This week, the team has been looking at congress planners, earnings call transcripts, and the US FDA.

This week, the team had Eyes on the new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.